Heat Biologics, Inc.
Heat Biologics, Inc. (HTBX) Revenue
Annual & quarterly revenue history · segment & region breakdown
HTBX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsHeat Biologics, Inc. trailing twelve-month (TTM) revenue is $6243B, a decrease of 28.33% year-over-year from $0.00B in FY2021.
Revenue trend
2021 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2021-12-31 | $0.00B | -$0.00B | -28.33% |
| 2020-12-31 | $0.00B | -$0.00B | -3.32% |
| 2019-12-31 | $0.00B | -$0.00B | -47.37% |
| 2018-12-31 | $0.01B | +$0.00B | +281.19% |
| 2017-12-31 | $0.00B | +$0.00B | +344.89% |
| 2016-12-31 | $0.00B | +$0.00B | — |
| 2015-12-31 | $0.00B | +$0.00B | — |
| 2014-12-31 | $0.00B | +$0.00B | — |
| 2013-12-31 | $0.00B | -$0.00B | -100.00% |
| 2012-12-31 | $0.00B | -$0.00B | -98.34% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Heat Biologics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Heat Biologics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Heat Biologics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
HTBX revenue · 4 questionsHTBX's trailing twelve-month (TTM) revenue is $6243B. That is a decrease of 28.33% year-over-year from $0.00B in FY2021.
▸ Source: FMP · Heat Biologics, Inc. SEC filings · GAAP · Heat Biologics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026